<DOC>
	<DOCNO>NCT00192309</DOCNO>
	<brief_summary>The primary objective study perform variety assay blood , serum , nasal wash cell sample obtain healthy adult subject purpose develop assay application investigation immune response generate influenza virus vaccine , trivalent , type A &amp; B , live , cold-adapted ( liquid formulation CAIV-T ; Wyeth , Marietta , PA ) .</brief_summary>
	<brief_title>Phase II Study Investigate Kinetics Immune Response Generated Influenza Virus Vaccine .</brief_title>
	<detailed_description>This randomize , open-label , placebo-controlled , outpatient study carry healthy adult 18 &lt; 65 year age . The study design evaluate kinetics immune response generate study product order determine best sampling time future study . Subjects randomize 1:1:1 ratio receive single dose either CAIV-T , inactivate influenza virus vaccine ( TIV ) , placebo .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects least 18 year age less 65 year age time inform consent obtain ; Women childbearing potential use reliable method hormonal and/or nonhormonal contraception ( include cervical cap , diaphragm , condom spermicide IUD ) sexual intercourse throughout entire study period ; negative urine pregnancy test ( detection limit less equal 25mIU/mL ) 24 hour prior vaccine administration ; agree avoid pregnancy participation study . A urine pregnancy test also conduct completion study participation . Females surgically sterile time enrollment require undergo pregnancy test . determine medical history , physical examination clinical judgement eligible study . provide write informed consent nature study explain ; available one month duration trial ( enrollment study completion ) ; could reach study staff postvaccination contact [ telephone , clinic home visit ] . perceive unavailable difficult contact evaluation study visit study period ; know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid intranasal steroid ; cytotoxic agent ; immunosuppressed immunocompromised individual living household ; document history hypersensitivity egg egg protein component study vaccine placebo ; receive commerciallyavailable investigational inject influenza vaccine 6 month prior enrollment , nonstudy influenza vaccine since enrollment ; previously receive intranasally administer influenza vaccine ; medical condition , opinion investigator , might interfere interpretation study result ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>